Quest Diagnostics Insider Sold Shares Worth $5.48 Million
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
Stocks · News reference
Deutsche Bank Adjusts Quest Diagnostics Price Target to $245
Deutsche Bank has updated its price target for Quest Diagnostics, moving it from $232 to $245 while maintaining a 'Hold' rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
DOT Consortium Integrates with Quest Diagnostics for New Compliance Testing Packages
DOT Consortium has launched new return-to-duty and follow-up testing packages on its online compliance platform, which integrates with Quest Diagnostics' laboratory network.
Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235
Evercore ISI has updated its price target for Quest Diagnostics, raising it from $235 to $240.
Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251
Rothschild & Co Redburn has increased its price target for Quest Diagnostics Incorporated, moving it from $251 to $279.
Quest Diagnostics Reports Cyber Breach Affecting Quanum Lab Services Manager
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum Lab Services Manager platform, potentially impacting patient data.
Quest Diagnostics Bumps Guidance While Managing Quanum System Breach
Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.